Britain and America have hammered out a key commercial pact that will keep no levies on UK medicine products entering the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to increase funding on medicines through the NHS. This pledge secures that duties on these vital goods will stay at nothing for a period of 36 months.
This agreement comes after previous statements to hike tariffs on patented drug products, with increases mentioned as high as double the cost.
"This deal between the Britain reinforces the worldwide climate for cutting-edge drugs and brings much-needed balance to American-British pharmaceutical trade," a statement said.
Economic Impact
Pharmaceuticals represent one of the Britain's biggest goods shipped to the America, which is clearly the biggest destination for leading UK drugmakers.
Statistics show that in the 12 months prior to the third quarter, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that period.
"This guarantee safeguards jobs, stimulates capital expenditure and sets the stage for the UK to emerge as a worldwide center for life sciences," a government official commented.
Specific UK Commitments
The deal involves several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must pay back to the NHS to control costs will be limited at 15%. Previously, rebates topped twenty percent.
Broader Context
The pact comes amid a long-running dispute between the sector and the UK government over spending levels and approval rates.
This friction were exacerbated by arguments that US customers were paying several times more for the identical medicines than patients in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a share of its resources over the last ten years.
